CJC-1295 / Ipamorelin vs GLP-3 RTA
CJC-1295 / Ipamorelin and GLP-3 RTA come from different research areas and are studied in largely separate models — researchers usually compare them when scoping a broader protocol.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do CJC-1295 / Ipamorelin and GLP-3 RTA differ?
CJC-1295 / Ipamorelin (Co-formulated GHRH-analog and secretagogue blend) is catalogued under longevity & cellular research; GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research. Verve lists 5 reported research applications for CJC-1295 / Ipamorelin and 5 for GLP-3 RTA. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | CJC-1295 / Ipamorelin | GLP-3 RTA |
|---|---|---|
| compound class | Co-formulated GHRH-analog and secretagogue blend | Synthetic triple-agonist peptide |
| research area | longevity & cellular | weight & metabolic |
| reported research applications | 5 listed | 5 listed |
| supplied as | co-formulated blend | single compound |
| catalog sizes | 10mg | 10mg · 20mg · 30mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | available | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $157.49 | $142.99 |
| availability | in stock | in stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is CJC-1295 / Ipamorelin and what is GLP-3 RTA?
CJC-1295 / Ipamorelin is classified as Co-formulated GHRH-analog and secretagogue blend; GLP-3 RTA as Synthetic triple-agonist peptide. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
CJC-1295 / Ipamorelin
Co-formulated GHRH-analog and secretagogue blend
CJC-1295 / Ipamorelin is a co-formulated research blend of two peptides that act at separate receptors. CJC-1295 without DAC, also referred to as Mod GRF 1-29, is a modified 29-amino-acid analog of growth-hormone-releasing hormone characterized as a GHRH-receptor agonist. Ipamorelin is a synthetic pentapeptide characterized as a selective agonist at the growth-hormone secretagogue receptor, GHS-R1a.
full CJC-1295 / Ipamorelin profile →GLP-3 RTA
Synthetic triple-agonist peptide
GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.
full GLP-3 RTA profile →Which research models is each compound studied in?
CJC-1295 / Ipamorelin sits in longevity & cellular research and GLP-3 RTA in weight & metabolic research, so their listed models largely do not intersect. The table lists 5 reported research applications for CJC-1295 / Ipamorelin and 5 for GLP-3 RTA. Rows are per compound, not equivalences.
| CJC-1295 / Ipamorelin — reported research applications | GLP-3 RTA — reported research applications |
|---|---|
| Dual-pathway GHRH-receptor and GHS-R1a signaling research | GLP-1, GIP, and glucagon receptor agonism research |
| Receptor cross-talk and signal-transduction research models | cAMP and class B GPCR signaling research models |
| Comparative agonist research versus single-component preparations | Comparative single-, dual-, and triple-agonist pharmacology studies |
| Endocrine-signaling research in cellular and pre-clinical models | Metabolic-pathway and nutrient-handling research models |
| Peptide stability and analog structure–activity research | Peptide half-life, lipidation, and stability research |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for CJC-1295 / Ipamorelin and GLP-3 RTA?
CJC-1295 / Ipamorelin is listed from $157.49 and GLP-3 RTA from $142.99. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| CJC-1295 / Ipamorelin | 10mg | $157.49 | in stock |
| GLP-3 RTA | 10mg | $142.99 | in stock |
| GLP-3 RTA | 20mg | $242.99 | in stock |
| GLP-3 RTA | 30mg | $328.99 | in stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about CJC-1295 / Ipamorelin and GLP-3 RTA
What is CJC-1295 / Ipamorelin?
It is a co-formulated research blend of CJC-1295 without DAC (also called Mod GRF 1-29), a GHRH analog, and ipamorelin, a selective GHS-R1a agonist. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is the difference between CJC-1295 with and without DAC?
The DAC (drug affinity complex) modification is a chemical addition studied for its effect on the analog's circulating half-life in pre-clinical models. The no-DAC form, Mod GRF 1-29, lacks that modification and is the component used in this blend.
What is GLP-3 RTA?
GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is GLP-3 RTA studied for in research?
In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.